Clinical Trial Update: Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a combination of romidepsin, CC-486 (oral azacitidine), dexamethasone, and lenalidomide (RAdR) for relapsed/refractory T-cell malignanc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Mature T-cell Malignancies
• Peripheral T-cell Lymphoma
• T-cell Malignancies

Drugs mentioned

• CC-486 (oral azacitidine) (azacitidine)
• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)
• Romidepsin (romidepsin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies | Phase 1 | Status: COMPLETED | Results posted: 2025-06-12